Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Prevalence of Cancer in Patients With Multiple Sclerosis (Ms) Who Received Rituximab: A Systematic Review and Meta-Analysis; [La Prevalencia De Cancer En Pacientes Con Esclerosis Multiple (Em) Que Recibieron Rituximab: Una Revision Sistematica Y Meta-Analisis] Publisher



Mirmosayyeb O1 ; Shaygannejad V1 ; Ebrahimi N1 ; Ghoshouni H1 ; Ghajarzadeh M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

Source: Neurologia Published:2025


Abstract

Objective: To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab. Methods: We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as ((“CD20 Antibody” AND Rituximab) OR “Rituximab CD20 Antibody” OR Mabthera OR “IDEC-C2B8 Antibody” OR “IDEC C2B8 Antibody” OR IDEC-C2B8 OR “IDEC C2B8” OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR “disseminated sclerosis” OR “multiple sclerosis” OR “acute fulminating”). Results: The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected. The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p < 0.001). Conclusion: The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases. © 2022
Related Docs
View other Related Docs
1. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
2. Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis, Acta Medica Iranica (2019)
3. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
4. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
5. Concurrent Glioma and Multiple Sclerosis: A Systematic Review of Case Reports, Multiple Sclerosis and Related Disorders (2024)
6. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
7. Cancer and Mortality Risks Among People With Multiple Sclerosis: A Population-Based Study in Isfahan, Iran, PLoS ONE (2024)
8. Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Autoimmunity Reviews (2021)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (19)
Masoud Etemadifar (14)
Other Related Docs
9. Cancer Risk Among Patients With Multiple Sclerosis: A Cohort Study in Isfahan, Iran, Caspian Journal of Internal Medicine (2017)
10. Rituximab Induced Cytokine Release Syndrome in an Ms Patient: A Case Report, Clinical Case Reports (2021)
11. Acute Relapse and Poor Immunization Following Covid-19 Vaccination in a Rituximab-Treated Multiple Sclerosis Patient, Human Vaccines and Immunotherapeutics (2021)
12. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
13. The Prevalence of Osteoporosis/Osteopenia in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
14. Evaluation of the Prevalence of Anti-Transglutaminase 2 and 6 Antibodies in Patients With Sero-Positive Multiple Sclerosis, Middle East Journal of Digestive Diseases (2024)
15. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
16. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
17. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
18. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
19. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
20. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
21. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
22. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
23. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
24. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
25. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies, Neurology: Neuroimmunology and NeuroInflammation (2024)
26. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
27. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
28. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
29. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
30. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
31. Efficacy and Safety of Rituximab in Neuromyelitis Optica: Review of Evidence, Journal of Research in Medical Sciences (2017)
32. Prevalence of Seizure/Epilepsy in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2021)
33. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
34. Cd24 Gene Allele Variation Is Not Associated With Oligoclonal Igg Bands and Igg Index of Multiple Sclerosis Patients, NeuroImmunoModulation (2012)
35. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
36. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
37. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
38. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
39. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
40. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
41. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
42. Insights Into the Interplay Between Epstein-Barr Virus (Ebv) and Multiple Sclerosis (Ms): A State-Of-The-Art Review and Implications for Vaccine Development, Health Science Reports (2024)
43. Lateonset Multiple Sclerosis in Isfahan, Iran, Archives of Iranian Medicine (2012)
44. Detection of Multiple Sclerosis Lesions by Susceptibility-Weighted Imaging—A Systematic Review and Meta-Analyses, Clinical Radiology (2024)
45. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
46. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
47. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)